Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

o advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119), is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad (RDEA594), BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-l
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
3. Ardea Biosciences Prices Public Offering of Common Stock
4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
(Date:9/12/2014)... Arthur Kay , the 23-year-old British founder of environmentally ... Challenge 2014. The jury, chaired by Ellen MacArthur ... final in Amsterdam to realize ... uses a patented process to upcycle waste coffee grounds ... used for powering buildings and transport systems. Bio-bean is ...
(Date:9/12/2014)... Sandia Biotech, Inc. announced today that the ... (STC) for a technology developed by researchers at the ... and Queen Mary University of London in London, England. ... Antibody Technology Platform (RFAP) was developed by Dr. Ravi ... Angray Kang from Queen Mary’s Department of Molecular Cell ...
(Date:9/11/2014)... thick sheet of carbon, can be randomly decorated with ... that could have a significant impact on the chemical, ... provide an ultra-strong, non-corrosive coating for a wide range ... be used to paint various surfaces ranging from glass ... chemical treatment, the resulting coatings behave like graphite in ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4Graphene paints a corrosion-free future 2
... Oct. 27 /Xinhua-PRNewswire/ -- Recently, China Green,Material ... Intellectual,Property Office for two patents for Industrialized ... and Industrialized Production,Method of Fully Biodegradable Edible ... applications have both obtained acceptance numbers,200810064592 and ...
... Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in,Development for Complicated ... Pneumonia (CAP), WASHINGTON, Oct. 27, 2008 ... detailed analysis of CANVAS I, a,globally conducted, multi-center, ... Conference on Antimicrobial Agents and Chemotherapy /,Infectious Diseases ...
... November 2, 2008 at this year,s liver ... - November 4, SAN FRANCISCO, Oct. 27 ... is no approved,medical therapy for this chronic progressive liver ... state-of-the-art lifestyle,intervention program. To do so, 31 overweight or ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2
(Date:9/15/2014)... lifeplants and animalsto thrive in the oceans, there ... In certain coastal areas, extreme oxygen-starvation produces "dead ... web structure. As dissolved oxygen levels decline, energy ... microbial community metabolism resulting in impacts on the ... the past 50 years, oxygen minimum zones (OMZs) ...
(Date:9/15/2014)... that affect hearing and cognitive function may play roles ... and perceive rhythm, pitch, timbre, tone durations, and formal ... BioEssays article explain that extremes in musical aptitude ... the majority of individuals having moderate aptitude. , "This ... to several underlying genes, and it is influenced to ...
(Date:9/15/2014)... hippopotamuses are demonstrably shown swimming or floating at the ... can,t swim, how did they reach and colonize islands? ... methods, patterns, and timing of the colonization and dispersal ... need to be reconsidered. , "Although land bridge connections ... currently supported by positive geological evidence, neither is ...
Breaking Biology News(10 mins):Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... The octopus arm is extremely flexible. Thanks to ... virtually infinite number of "degrees of freedom"--the octopus ... movements that is unmatched by the human arm. ... differences between the octopus and vertebrates, the octopus ...
... Environmental and genetic factors lead to neural tube defects in 1 ... spontaneous abortion. One cause of these defects is the failure of ... the developing neural tube. , A study in ... the molecular mechanism that directs cells to migrate to the correct ...
... in food-producing animals may be linked with lower levels ... an article in the May 15 issue of Clinical ... is a leading bacterial cause of foodborne illness in ... for physicians to treat, and can result in longer ...
Cached Biology News:How the octopus forms an elbow 2Less antibiotic use in food animals leads to less drug resistance in people, study shows 2
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
Biology Products: